Evaluating and Monitoring Immune and Clinical Responses in Early-Stage Triple Negative Breast Cancer Undergoing Neoadjuvant Chemo-immunotherapy With Pembrolizumab

Recruiting

Chemo-ImmunotherapyEvaluating and Monitoring Immune and Clinical Responses in Early-Stage Triple Negative Breast Cancer Undergoing Neoadjuvant Chemo-immunotherapy With Pembrolizumab

Sponsor:

Emory University

Code:

NCT05877859

Conditions

Breast Cancer Triple Negative

Breast Cancer Stage II

Breast Cancer Stage III

Breast Cancer Invasive

Eligibility Criteria

Sex: Female

Age: 18+

Healthy Volunteers: Accepted

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-07-10. This information was provided to ClinicalTrials.gov by Emory University on 2026-05-07.